Houston-based Innowatts closed its Series B funding round — a $18.2 million commitment from the likes of Energy Impact Partners, Shell Ventures, and more. Photo via innowattts.com

Houston-based Innowatts has closed its Series B funding round lead by Energy Impact Partners. The company, which enables artificial intelligence through its retail energy technology platform, secured a $18.2 million investment. Current funders also include Shell Ventures, Iberdrola, and Energy and Environment Investment (EEI Japan) — which all three supported the company in its Series A — along with new investor Evergy Ventures.

The funds will be used to grow the company's eUtilityTMplatform technology — a B2B cloud-based software tool to help retail energy providers better deliver quality energy services and insights to clients. The eUtilityTM platform already processes meter data from over 21 million customers globally and across 13 regional energy markets, according to the release.

"Competing in today's complex and evolving marketplace requires utility companies use data and intelligence to drive business and customer value," says Siddhartha Sachdeva, founder and CEO of Innowatts, in a release. "Energy Impact Partners, along with its coalition of innovative utility investors, appreciates the role that the eUtilityTM platform can play in creating a smarter, more efficient energy value chain. We're excited to have EIP join us on the next phase of our journey in building the digital utility of the future."

The company is "poised to become a key building block in the software-driven, intelligent grid of the future," says Michael Donnelly, partner and chief risk officer at EIP in the release.

"We invest in companies driving the transformation of the energy sector towards an increasingly decarbonized, digitized, and electrified future – solutions that our utility partners can commercialize at scale and have the greatest impact," Donnelly continues.

Innowatts' $6 million Series A round closed in August 2017. Shell Ventures lead that round.

"Utilities have the opportunity to deliver more value to customers, at lower costs and with greater personalization than ever before, while helping streamline the complex energy marketplace," says Geert van de Wouw, vice president Shell Ventures, in a release. "The predictive customer intelligence and digital solutions provided by Innowatts' eUtilityTM platform is central to executing that vision."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”